Table 2.
Association of the SI to drugs and clinical characteristics of patient and parameters of STS tumors (Mann–Whitney test), р-value.
| Characteristics | n, % | Dox | Ifo | Dox + Ifo | Doc | Gem | Doс + Gem |
|---|---|---|---|---|---|---|---|
| SI, mean ± SD | 70 | 293 ± 120 | 328 ± 167 | 238 ± 130 | 401 ± 145 | 374 ± 164 | 297 ± 172 |
| Age | |||||||
| <40 >40 |
23 (33%) 46 (67%) |
0.01 * (higher resistance in >40 group) |
0.41 | 0.10 | 0.08 | 0.08 | 0.17 |
| Gender | |||||||
| Female Male |
33 (47%) 37 (53%) |
0.49 | 0.54 | 0.82 | 0.70 | 0.89 | 0.16 |
| Tumor size | |||||||
| T1–T2 Т3–Т4 |
38 (54%) 32 (46%) |
0.89 | 0.30 | 0.46 | 0.78 | 0.39 | 0.62 |
| Histology types | |||||||
| Undifferentiated pleomorphic sarcoma Liposarcoma Synovial sarcoma Others |
24 (34%) 16 (23%) 11 (16%) 19 (27%) |
0.04 * (Undifferentiated pleomorphic sarcoma more resistance) |
0.74 | 0.62 | 0.12 | 0.34 | 0.13 |
| Tumor grade | |||||||
| G1–G2 G3 |
10 (15%) 56 (85%) |
0.19 | 0.10 | 0.08 | 0.27 | 0.26 | 0.15 |
| Newly diagnosed (without NeoCT) vs. Recurrent |
22 (39%) 35 (61%) |
0.11 | 0.59 | 0.18 | 0.63 | 0.92 | 0.86 |
| Treatment characteristics | |||||||
| Chemotherapy (all patient) | |||||||
| No Yes |
34 (49%) 36 (51%) |
0.23 | 0.21 | 0.72 | 0.89 | 0.35 | 0.64 |
| Newly diagnosed vs. Newly diagnosed with NeoCT |
22 (59%) 15 (41%) |
0.32 | 0.92 | 0.98 | 0.21 | 0.16 | 0.06 |
| Tumor regression grade | |||||||
| 0–1 2–3 |
17 (73%) 6 (27%) |
0.11 | 0.31 | 0.49 |
0.0014 ** (higher resistance in 2–3 grade group) |
0.25 | 0.06 |
| Tumor regression grade after NeoCT | |||||||
| 0–1 2–3 |
10 (71%) 4 (29%) |
0.053 | 0.29 | 0.55 |
0.008 ** (higher resistance in 2–3 grade group) |
0.053 |
0.03 * (higher resistance in 2–3 grade group) |
NeoCT—neoadjuvant chemotherapy; * p-value < 0.05; ** p-value < 0.01.